TSHA Q4 2021 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$50M

Net Income

-$50M

EPS (Diluted)

$-1.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$49M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$214M

Total Liabilities

$119M

Stockholders' Equity

$95M

Cash & Equivalents

$149M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$50M	-$18M	-170.7%
Net Income	-$50M	-$18M	-175.1%